The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors.
Jingquan Jia
No relevant relationships to disclose
Haiyan Li
No relevant relationships to disclose
Andrew Dellinger
No relevant relationships to disclose
Herbert Pang
No relevant relationships to disclose
Karen Bullock Russell
No relevant relationships to disclose
Herbert Hurwitz
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Research Funding - Novartis; Roche/Genentech
Andrew B. Nixon
Research Funding - Roche/Genentech